These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29356578)

  • 1. No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis.
    Dutil J; Godoy L; Rivera-Lugo R; Arroyo N; Albino E; Negrón L; Monteiro AN; Matta JL; Echenique M
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):85-89. PubMed ID: 29356578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy.
    Anczuków O; Buisson M; Léoné M; Coutanson C; Lasset C; Calender A; Sinilnikova OM; Mazoyer S
    Clin Cancer Res; 2012 Sep; 18(18):4903-9. PubMed ID: 22753590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients.
    De Silva S; Tennekoon KH; Dissanayake A; De Silva K; Jayasekara L
    Fam Cancer; 2017 Jul; 16(3):329-338. PubMed ID: 28039656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer.
    Diop JPD; Diallo RN; Bourdon-Huguenin V; Dem A; Diouf D; Dieng MM; Ba SA; Dia Y; Ka S; Mbengue B; Thiam A; Faye O; Diop PA; Sobol H; Dieye A
    BMC Med Genet; 2019 May; 20(1):73. PubMed ID: 31060517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India.
    Saxena S; Chakraborty A; Kaushal M; Kotwal S; Bhatanager D; Mohil RS; Chintamani C; Aggarwal AK; Sharma VK; Sharma PC; Lenoir G; Goldgar DE; Szabo CI
    BMC Med Genet; 2006 Oct; 7():75. PubMed ID: 17018160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
    Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
    Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
    Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
    Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of BRCA2 Splicing Variants: A Case Series of Challenging Variant Interpretations and the Importance of Functional RNA Analysis.
    Nix P; Mundt E; Coffee B; Goossen E; Warf BM; Brown K; Bowles K; Roa B
    Fam Cancer; 2022 Jan; 21(1):7-19. PubMed ID: 33469799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
    Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
    Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
    Solodskikh SA; Panevina AV; Gryaznova MV; Gureev AP; Serzhantova OV; Mikhailov AA; Maslov AY; Popov VN
    Mutat Res; 2019 Jan; 813():51-57. PubMed ID: 30611917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays.
    Fraile-Bethencourt E; Valenzuela-Palomo A; Díez-Gómez B; Goina E; Acedo A; Buratti E; Velasco EA
    J Pathol; 2019 Aug; 248(4):409-420. PubMed ID: 30883759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Significant Unclassified Variants in
    Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
    Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRCA2 genetic variant IVS7 + 2T-->G is a mutation.
    Pyne MT; Brothman AR; Ward B; Pruss D; Hendrickson BC; Scholl T
    J Hum Genet; 2000; 45(6):351-7. PubMed ID: 11185744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members.
    Thomassen M; Blanco A; Montagna M; Hansen TV; Pedersen IS; Gutiérrez-Enríquez S; Menéndez M; Fachal L; Santamariña M; Steffensen AY; Jønson L; Agata S; Whiley P; Tognazzo S; Tornero E; Jensen UB; Balmaña J; Kruse TA; Goldgar DE; Lázaro C; Diez O; Spurdle AB; Vega A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1009-23. PubMed ID: 21769658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.